Merck Serono taps Threshold for Ph III cancer drug
This article was originally published in Scrip
Executive Summary
Merck KGaA has paid €19 million ($25 million) up front to access a small-molecule drug targeting tumour hypoxia from Threshold Pharmaceuticals of South San Francisco, California. The compound, TH-302, is in Phase III for soft tissue sarcoma and in Phase II for advanced pancreatic cancer, with results expected for the latter in the next few days. Threshold noted that total milestone payments could reach $525 million, with $280 million related to regulatory and development milestones and $245 million from sales-based milestones.